NovoCure Limited (NVCR)

NASDAQ: NVCR · IEX Real-Time Price · USD
13.57
-0.55 (-3.90%)
At close: Apr 12, 2024, 4:00 PM
13.99
+0.42 (3.10%)
After-hours: Apr 12, 2024, 7:49 PM EDT
-3.90%
Market Cap 1.45B
Revenue (ttm) 509.34M
Net Income (ttm) -207.04M
Shares Out 107.09M
EPS (ttm) -1.95
PE Ratio n/a
Forward PE 909.09
Dividend n/a
Ex-Dividend Date n/a
Volume 882,522
Open 14.01
Previous Close 14.12
Day's Range 13.40 - 14.12
52-Week Range 10.87 - 83.60
Beta 0.43
Analysts Buy
Price Target 45.89 (+238.17%)
Earnings Date May 2, 2024

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporate... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Oct 2, 2015
Employees 1,453
Stock Exchange NASDAQ
Ticker Symbol NVCR
Full Company Profile

Financial Performance

In 2023, NovoCure's revenue was $509.34 million, a decrease of -5.30% compared to the previous year's $537.84 million. Losses were -$207.04 million, 123.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $45.89, which is an increase of 238.17% from the latest price.

Price Target
$45.89
(238.17% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Can...

8 days ago - Business Wire

Novocure to Report First Quarter 2024 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financi...

12 days ago - Business Wire

Novocure's stock surges after positive results in brain-cancer trial

Novocure Ltd.'s stock soared 15% Wednesday after the company announced positive results from a late-stage trial of a medtech device to treat patients with lung cancer that has spread to their brains.

17 days ago - Market Watch

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) partner Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demo...

Other symbols: ZLAB
17 days ago - Business Wire

Novocure's lung cancer therapy succeeds in late-stage trial

Novocure said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer.

17 days ago - Reuters

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement i...

17 days ago - Business Wire

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 /...

4 weeks ago - Business Wire

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023. Novocure is a global oncology company work...

7 weeks ago - Business Wire

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) the...

3 months ago - Business Wire

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and ef...

3 months ago - Business Wire

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 20...

3 months ago - Business Wire

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a prov...

3 months ago - Business Wire

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. Willi...

3 months ago - Business Wire

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

ROOT, Switzerland--(BUSINESS WIRE)--Novocure today announced a series of actions to strengthen and optimize business operations to support growth drivers and long-term value creation.

4 months ago - Business Wire

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.

5 months ago - Business Wire

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and...

5 months ago - Business Wire

Novocure Reports Third Quarter 2023 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023.

6 months ago - Business Wire

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid...

6 months ago - Business Wire

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treat...

6 months ago - Business Wire

Novocure to Report Third Quarter 2023 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced that it will report financial results for the third quarter 2023 on October 26, 2023, before the U.S. financial markets open.

6 months ago - Business Wire

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October...

7 months ago - Business Wire

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Confer...

7 months ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limite...

8 months ago - Accesswire

Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) ...

8 months ago - Business Wire

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limite...

8 months ago - Accesswire